BioWorld MedTech

April 26, 2011

Boston Sci receives approval for ION DES

Boston Scientific (BSX; Natick, Massachusetts) reported approval and launch of the Ion paclitaxel-eluting platinum chromium coronary stent system, the company's third-generation drug-eluting stent (DES) technology. (Medical Device Daily) Read More

Gore reports the enrollment of first TIPS study patient

International report: CryoLife to distribute BioGlue in Japan

Washington roundup: Updated human factors guidance requires further clinical data

Agreements/contracts: Philips, NEC combine their digital pathology solutions

Coming Wednesday in MDD Perspectives: Industry and public can help provide safeguards against unethical research

Court Report: Jury awards St. Jude $2.3B in trade secret violations case

Financings roundup: Oxford Finance gets new $460M capital infusion

Deals roundup: Tenet board again rejects acquisition offer from CHS

Product Briefs

People in the News

MDD's Cardio Extra

Today's news in brief

BioWorld

BioWorld briefs for Jan 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 12, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Science in 2025: the best of the rest

BioWorld Science

A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...